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lished head to head comparisons between all AAPs, response
rates were obtained from individual studies for each AAP. Total
annual costs were calculated based on 1.3 acute manic episodes
per year and included costs of AAPs, concurrent medications,
adverse events, and medical resource utilization. All costs were
inﬂated to 2005 values. Incremental cost-effectiveness and sen-
sitivity analyses will be conducted. RESULTS: The total annual
costs per patient were $7897, $7778, $7807, $7730, and $7829
for aripiprazole, ziprasidone, risperidone, quetiapine, and 
olanzapine, respectively. Given the response rates and costs per
patient listed above, the CE ratios were $17,356, $15,555,
$13,360, $14,504, and $13,807, respectively. CONCLUSIONS:
These ﬁndings suggest that, among AAPs, treatment with risperi-
done may be the most cost-effective choice for acute manage-
ment of mania in patients with bipolar I disorder. The results of
this model are limited to a 3-week acute treatment of mania, thus
no conclusions can be drawn about the cost-effectiveness of
AAPs when used as maintenance treatment.
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OBJECTIVES: To assess changes in cost and effectiveness para-
meters following switch from risperidone to olanzapine during
the long-term treatment of schizophrenia patients. METHODS:
Patients were participants in a randomized, open-label, 1-year
cost-effectiveness trial of olanzapine, risperidone, and typical
antipsychotics in the treatment of schizophrenia. Study protocol
permitted antipsychotic switching when clinically warranted.
Resource utilization was systematically abstracted from medical
records. Treatment outcomes were assessed with standard 
psychiatric measures. Statistical analyses assessed changes from
pre-to-post switch among patients who were randomized to
risperidone, but later switched to olanzapine for any cause.
RESULTS: Sixty of the 218 (27.5%) patients randomized to
risperidone switched antipsychotics—with 43 (72%) switching
to olanzapine. Average duration on risperidone before switching
to olanzapine was 86.1 days (mean maximum dose 4.5mg/day).
Most of these switchers (86%) completed the 1-year study on
olanzapine (average maximum dose 13.3mg/day). Following
switch to olanzapine, patients experienced signiﬁcant improve-
ments on clinical and social parameters (both, p < 0.001), with
35.7% of the prior non-remitters achieving remission status.
Mean total daily costs changed from $49.5/day pre-switch, to
$44.4/day post-switch (non-signiﬁcant difference). CONCLU-
SIONS: Olanzapine appears to be a cost effective “rescue”
option for patients who require switching from risperidone in
the long-term treatment of schizophrenia.
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OBJECTIVES: Chronic schizophrenia is a high prevalence
disease in Mexico which generates signiﬁcant disabilities and
economic expenditures on the Mexican Health System. The
purpose of the study was to model the economic consequences
of adverse events (AE) related with ﬁve antipsychotic drugs in
adult patients in the Social Security Mexican Institute.
METHODS: A cost–effectiveness model was developed using a
Markov modeling approach. The model simulated treatment of
a cohort of 1000 schizophrenics for twelve months, initiating
treatment with one of ﬁve antipsychotic drugs; haloperidol (10
mg), ziprasidone (80mg), risperidone (4mg), olanzapine (15mg)
and clozapine (300mg). Conditional probabilities of developing
any AE (akathisia, weight gain, extrapyramidal symptoms) were
obtained according to clinical trials previously published and
were adjusted with local expert opinion surveys. Treatment was
susceptible to be modiﬁed (decrease dose, switch medication).
Effectiveness measure was the number of free months of psy-
chotic symptoms. The analysis was conducted from the health-
care payer’s perspective (only direct medical costs were used).
Resource use and costs were obtained from hospital records of
the biggest psychiatric hospital in Mexico (“Hospital San 
Fernando”). Probabilistic sensitivity analysis was performed 
and acceptability curves were constructed. RESULTS: Zipra-
sidone showed the lower expected annual costs per patient
(US$17,159.5 ± 7,605.1) and the higher number of free months
of psychotic symptoms (9.2 ± 1.5 months). Ziprasidone was 
followed by risperidone and clozapine who obtained annual
expected costs of US$19,589.2 and US$24,656.1; and effective-
ness of 8.8 and 8.9 months, respectively. Results were robust to
Monte Carlo second order sensitivity analysis. Acceptability
curves showed the same results with a mean of 60% of certainty.
CONCLUSIONS: In Mexico, ziprasidone resulted the treatment
most cost–effective, followed by risperidone, clozapine and olan-
zapine. These results should be taken into account by Mexican
decision makers and clinicians in the management of patients
with chronic schizophrenia.
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OBJECTIVES: This study examined health care and resource 
utilization associated with atypical antipsychotic treatment for
bipolar disorder. METHODS: Using the NC Medicaid Claims
database 3328 patients were identiﬁed who had 3 months pre-
and 12 months post-treatment initiation data. Patients diagnosed
with bipolar disorder were classiﬁed into three groups based on
type of treatment during the ﬁrst 30 days after treatment initia-
tion (index date): atypical antipsychotic (AP2) monotherapy,
atypical antipsychotic plus mood stabilizer (AP2 + MS) combi-
nation therapy, and mood stabilizer (MS) monotherapy. For the
12 month treatment period, total bipolar-related and total
health-related costs were examined including and excluding
index medication. Comparative costs of index medications were
also analyzed. Propensity score matching was employed to
balance baseline characteristics between the three comparison
groups. Gamma regression models were further employed to 
estimate the average treatment effect on the cost outcomes.
RESULTS: Compared to MS monotherapy, AP2 monotherapy
and AP2 + MS therapy incurred higher index medication costs
during the treatment period. Patients on AP2 monotherapy
incurred signiﬁcantly lower total health-related costs excluding
index medication (-10.9%, p < 0.046), leading to no statistical
difference in total health-related cost including index medication
(1.5%, p < 0.76). In terms of total bipolar-related costs, patients
on AP2 monotherapy had higher costs than MS monotherapy
when including index medication costs (14.9%, p < 0.01).
However, bipolar-related costs excluding index medication cost
was signiﬁcantly lower (-16.7%, p < 0.03). Results were similar
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when comparing AP2 + MS therapy with MS monotherapy.
CONCLUSIONS: In terms of non-index medication health-
related costs, AP2 monotherapy was more cost saving than MS
monotherapy in the treatment of bipolar disease. In terms of
non-index medication bipolar-related costs, AP2 monotherapy
and AP2 + MS therapy was more cost saving than MS monother-
apy. However, when the cost of AP2 treatment was included, no
signiﬁcant differences were found.
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OBJECTIVES: To evaluate the direct health care costs associated
with olanzapine, risperidone, and quetiapine monotherapy
among patients diagnosed with bipolar disorder (ICD-9: 296.4x-
296.8x). METHODS: Using a sample drawn from the NC Med-
icaid Claims database during August 2000 through January
2005. This study included patients with a bipolar-related diag-
nosis who were naïve to atypical antipsychotic treatment and
were without a bipolar-related medical visit or hospitalization
during 90 days prior to treatment initiation. Patients were fol-
lowed for 12 months after initiation of atypical antipsychotic
monotherapy (index drug). Costs of index drug, all bipolar-
related medical care, and all health-related costs, both including
and excluding index drug, were examined in the 12 month treat-
ment period using Generalized Linear Model with Gamma 
Distribution and Log link. To account for potential confounds,
the model included several covariates. RESULTS: A total of 838
continuously eligible patients met the inclusion criteria (393
olanzapine, 262 risperidone and 183 quetiapine). The costs of
index drug for patients taking olanzapine were 43% (P < 0.0001)
and 19% higher (p < 0.0001) than risperidone and quetiapine,
respectively. In terms of total health-related cost there was no
difference between patients treated with olanzapine and those
treated with risperidone or quetiapine, including or excluding
index drug. In terms of all bipolar-related medical care costs, the
inclusion of index drug led to 15.2% (p < 0.04) higher costs 
for patients receiving olanzapine compared to risperidone, 
primarily due to the higher acquisition cost of olanzapine. 
CONCLUSIONS: Despite signiﬁcantly higher acquisition costs
of olanzapine when used as mono-therapy for the treatment of
bipolar disorder, total health-related costs with and without
index drug were similar for olanzapine, risperidone and queti-
apine. Bipolar-related medical costs excluding index drug were
also similar for olanzapine, risperidone, and quetiapine treat-
ment. However, the inclusion index drug costs resulted in higher
bipolar-related medical costs for patients receiving olanzapine
compared to risperidone.
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OBJECTIVE: To examine the acute adverse outcomes and direct
health care costs among patients with Alzheimer’s disease (AD)
using a retrospective, administrative claim database.
METHODS: We identiﬁed an over-age-65 population with phar-
macy and medical beneﬁts enrolled in a large, US, geographically
diverse, commercial managed care plan between May 2001 and
December 2002. AD patients had at least one claim with an AD
diagnosis or one ﬁlled prescription for medication used exclu-
sively for AD treatment. This claim identiﬁed the index date. A
control cohort consisted of non-AD patients with no dementia
diagnosis over the pre- and post-index periods randomly
matched (3 :1) to the AD patients by age, gender, plan location,
and length of enrollment. The ﬁrst claim in the period identiﬁed
the index date. All patients included in the study had a 12-month
pre-index period, and a minimum of 30-days follow-up. We
compared the prevalence of acute adverse outcomes and comor-
bidities between the AD and control cohorts. Additionally, we
used a two-part model (one equation estimating the probability
of any costs, and a generalized linear model with a gamma dis-
tribution and log-link function estimating the level of costs) to
examine differences in adjusted annualized total health care costs
between the AD patients and the controls. RESULTS: Both the
AD patients (N = 4,550) and the controls (N = 13,650) had a
mean age of 79 years. Approximately 70% of AD patients were
identiﬁed based on an AD prescription. AD patients had a higher
risk of fracture, accidental fall, and urinary tract infection than
the controls. Annual adjusted total health care costs per patient
were approximately $1418 greater for the AD cohort. 
CONCLUSIONS: AD patients had signiﬁcantly greater risk 
of acute adverse outcomes and more health care resource 
utilization than age- and gender-matched controls in a large
managed care plan.
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OBJECTIVES: To examine the direct medical costs of newly
diagnosed patients with Alzheimer’s disease (AD) using retro-
spective health care claims data. METHODS: This study exam-
ined individuals aged 65 years and over with pharmacy beneﬁts
who had at least one claim with an AD diagnosis and were
enrolled in commercially-insured and nationally-dispersed
Medicare Risk plans between January 1999 and November
2003. Each AD patient had an “index date” where the ﬁrst AD
claim was observed, a 12-month pre-index period, and a
minimum 30-day follow-up. A control group consisted of indi-
viduals who had no AD or dementia over the study period and
were randomly matched (2 :1) to AD patients based on age,
gender, and follow-up duration. The Charlson Comorbidity
Index was used to examine the burden of comorbid medical con-
ditions in the pre-index period. The primary measures of inter-
est were annualized health care resource utilization and costs; a
generalized linear model with a gamma distribution and log-link
function was used to compare costs between the AD and control
groups over the follow-up period. RESULTS: Both AD patients
(n = 2475) and controls (n = 4950) were aged 82 years on
average; 38% were male. AD patients had signiﬁcantly more
comorbid medical conditions than controls (mean Charlson
score 1.6 vs. 1.2); the prevalence of diabetes, heart and vascular
problems also was higher in the AD group. Inpatient costs con-
tributed primarily to total annualized costs among AD patients,
while outpatient costs dominated among controls. Average
adjusted annualized costs for AD patients were more than ﬁve-
fold higher compared to controls, driven primarily by inpatient
costs ($21,150 vs. $4,053 for AD vs. control, respectively).
CONCLUSIONS: AD patients have a signiﬁcantly greater
